<DOC>
<DOCNO>
EP-0002264
</DOCNO>
<TEXT>
<DATE>
19790613
</DATE>
<IPC-CLASSIFICATIONS>
C07K-7/56 C07K-1/113 C07K-14/435 A61K-38/04 C07K-1/00 C07K-7/00 C07K-14/655 C07K-14/575 <main>C07C-103/52</main> A61K-37/02 A61K-38/00 A61P-43/00 
</IPC-CLASSIFICATIONS>
<TITLE>
somatostatin analogs, process for their preparation and pharmaceutical composition thereof.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc.<sep>
</APPLICANT>
<INVENTOR>
veber daniel frank<sep>veber, daniel frank<sep>veber, daniel frank290 batleson road19002 ambler pennsylvaniaus<sep>veber, daniel frank<sep>veber, daniel frank290 batleson road19002 ambler pennsylvaniaus<sep>
</INVENTOR>
<ABSTRACT>
bicyclic somatostatin analogs and pharmaceutically  acceptable non-toxic acid addition salts thereof are prepared  by the solid phase method.  these analogs have the property  of inhibiting the release of growth hormone without affecting  the level of gastric secretions or without affecting the level of  gastric secretions, insulin and glucagon in humans and  animals.  the compounds are particularly useful in the  treatment of acromegaly and diabetic retinopathy.  due to the  bicyclic structure, these analogs are resistant to enzymatic  metabolism and have a longer duration of activity than  somatostatin.  
</ABSTRACT>
</TEXT>
</DOC>
